Teva’s Copaxone Successor Fails in Latest Clinical Trial

Teva Pharmaceutical Industries Ltd.’s experimental multiple sclerosis pill failed to reduce relapses more than placebo in a clinical trial, dealing a blow to the company’s effort to find a successor to an older drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.